Summit Therapeutics Receives FDA Fast Track Designation for Novel Antibiotic SMT19969 in the Treatment of C. difficile Infection

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.